文献速递头颈部肿瘤放疗姑息放疗与转移瘤

新发转移性鼻咽癌根治性放疗候选者的预后模型开发

Development of a Prognostic Model to Identify the Suitable Definitive Radiation Therapy Candidates in de Novo Metastatic Nasopharyngeal Carcinoma: A Real-World Study.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-08-24

本研究纳入460例新发转移性鼻咽癌患者,244例接受姑息化疗联合根治性放疗,216例仅接受姑息化疗。逆概率加权Cox回归显示联合根治性放疗与生存获益显著相关(HR 0.516,95%CI 0.403-0.660,P<.001)。基于5个独立预后因素构建的预后模型可识别适合根治性放疗的低危患者,高危患者未能从额外根治性放疗中获益。

要点

  • 姑息化疗后加根治性放疗与新发转移性鼻咽癌总生存改善相关(HR 0.516)。
  • 基于5因素预后模型可区分根治性放疗获益人群,低危患者生存获益显著。
  • 高危患者未能从额外根治性放疗中获益,保险与教育水平影响放疗接受。

核心结论

  • 姑息化疗后加根治性放疗与新发转移性鼻咽癌总生存改善相关,尤其经新预后模型识别的低危患者。

研究设计与样本

  • 真实世界研究纳入460例接受一线姑息化疗(联合或不联合根治性放疗)的新发转移性鼻咽癌患者。
  • 采用逆概率治疗加权调整的生存分析比较单纯姑息化疗与姑息化疗联合根治性放疗的总生存。
  • 开发并验证预后模型,结合基于模型的树方法估计分层治疗效果,并用优势分析确定预测因素相对重要性。

主要发现

  • 244例接受姑息化疗联合根治性放疗,216例仅接受姑息化疗。
  • 6个月条件里程碑逆概率加权Cox回归显示联合根治性放疗与显著生存获益相关(HR 0.516;95%CI 0.403-0.660;P<.001)。
  • 基于血清乳酸脱氢酶、转移部位数、肝转移 presence、治疗后EB病毒DNA水平及转移灶对化疗反应5个独立预后因素构建并验证预后模型。
  • 模型识别的低危患者从额外根治性放疗中获得显著生存获益,高危患者未获益。
  • 保险状态和教育水平等社会经济因素在接受根治性放疗中起重要作用。

关键数值与推荐

  • 预后模型包含5个独立预后因素:血清乳酸脱氢酶、转移部位数、肝转移 presence、治疗后EB病毒DNA水平、转移灶对化疗反应。
  • 联合根治性放疗 vs 单纯姑息化疗的总生存HR为0.516(95%CI 0.403-0.660,P<.001)。

临床怎么用

  • 对新发转移性鼻咽癌患者,可依据该预后模型进行风险分层,低危患者考虑在姑息化疗基础上加根治性放疗。
  • 高危患者可能不宜常规加用根治性放疗,需结合社会经济因素综合评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We aimed to develop an accurate prognostic model to identify suitable candidates for definitive radiation therapy (DRT) in addition to palliative chemotherapy (PCT) among patients with de novo metastatic nasopharyngeal carcinoma (mNPC). METHODS AND MATERIALS: Patients with de novo mNPC who received first-line PCT with or without DRT were included. Overall survival for patients who received PCT alone versus PCT plus DRT was estimated using inverse probability of treatment weighting-adjusted survival analyses. We developed and validated a prognostic model to predict survival and stratify risks in de novo mNPC. A model-based trees approach was applied to estimate stratified treatment effects using prognostic scores obtained from the prognostic model and to identify suitable DRT candidates. Dominance analysis was used to determine the relative importance of each predictor of receiving DRT. RESULTS: A total of 460 patients were enrolled; 244 received PCT plus DRT and 216 received PCT alone. The 6-month conditional landmark, inverse probability of treatment weighting-adjusted Cox regression analysis showed that PCT plus DRT was associated with a significant survival benefit (hazard ratio: 0.516; 95% confidence interval, 0.403-0.660; P < .001). A prognostic model based on 5 independent prognostic factors, including serum lactate dehydrogenase, number of metastatic sites, presence of liver metastasis, posttreatment Epstein-Barr virus DNA level, and response of metastases to chemotherapy was developed and subsequently validated. Prognostic scores obtained from the prognostic model were used for risk stratification and efficacy estimation. High-risk patients identified using the proposed model would not benefit from additional DRT, whereas low-risk patients experienced significant survival benefits. Socioeconomic factors, including insurance status and education level, played an important role in receipt of DRT. CONCLUSIONS: Additional DRT after PCT was associated with increased overall survival in patients with de novo mNPC, especially low-risk patients identified with a newly developed prognostic model.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Li WZ, Lv SH, Liu GY, et al. Development of a Prognostic Model to Identify the Suitable Definitive Radiation Therapy Candidates in de Novo Metastatic Nasopharyngeal Carcinoma: A Real-World Study. Int J Radiat Oncol Biol Phys. 2020. PMID: 32853711. doi:10.1016/j.ijrobp.2020.08.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。